Latest News | Cipla Partners Premier Medical Corporation to Launch COVID-19 Rapid Antigen Test Kits in India

New Delhi, Dec 16 (PTI) Drug major Cipla on Wednesday announced its partnership with the Premier Medical Corporation Pvt Ltd for commercialisation of the rapid antigen test kits for COVID-19 in India.

"In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Pvt Ltd," Cipla said in a regulatory filing.

Also Read | Microsoft Launches New Office Apps for M1 Chip-Powered Apple Macs.

The company said it will commence supply of rapid point-of-care nasopharyngeal swab tests from this week.

The test will be marketed under the brand name 'CIPtest'.

Also Read | Sensex Up 288 Points at 46,551, Nifty at 13,650 in Opening Trade.

Shares of Cipla were trading 0.29 per cent higher at Rs 783.95 apiece on the BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)